Relapsed or Refractory EBV-and CD30-positive Lymphomas
1 clinical trials · Condition
◉ Watch Relapsed or Refractory EBV-and CD30-positive Lymphomas
| Record | Firm | Date |
|---|---|---|
| Brentuximab Vedotin in Patients With Relapsed or Refractory EBV-and CD30-positive Lymphomas (NCT02388490) | Seoul National University Hospital | 2016-03-25 |
Track Relapsed or Refractory EBV-and CD30-positive Lymphomas automatically
Every clearance here is in the API, with alerts when new ones post.